[Discussion] amylin is doing more work than we give it credit for
amylin is doing more work than we give it credit for. Not a hot take, just something I have not seen said plainly here.
Sent a vial to Medutest because there was almost nothing on file for this compound. 99.5% against a claimed 99.0%, and I posted it because the log needs entries.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
long-acting amylin is the whole point of the molecule
the interesting data is the combination, not the monotherapy
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
[removed by moderator]
do not assume the dosing intuitions from the GLP-1 boards transfer
read the combination arms separately from the monotherapy arms
Is there any independent purity data on this compound that you have seen?
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
nausea profile in the combination trials is the thing to read carefully
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
this is a less-travelled board and the evidence base shows it
Cosigning on the thin independent data. Fewer members test this, so the bands are wider and should be treated that way.
Cosigning on the thin independent data.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
satiety signalling rather than incretin signalling
independent purity data on this compound is thin
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
nothing containing this is approved as a standalone product
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
the monotherapy numbers are modest and that is not the point
the co-agonism argument is about complementary mechanisms
- 1the interesting data is the combination, not the monotherapy11 comments in this branch · started by u/b12_baseline
- 2Cosigning on the thin independent data. Fewer members test this, so the…8 comments in this branch · started by u/tomas_kimani